baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Zai Lab Limited/ US98887Q1040 /

2024-09-20 9:59:59 PM	Chg. +0.78	Volume	Bid-	Ask-	High	Low
21.88USD	+3.70%	30,246 Turnover: 643,434.82	-Bid Size: -	-Ask Size: -	21.88	20.80

GlobeNewswire 07-31 Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacyclin...

GlobeNewswire 07-18 Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Stu...

GlobeNewswire 07-16 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...

GlobeNewswire 06-01 Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipa...

GlobeNewswire 04-18 Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated P...

GlobeNewswire 01-04 Former Biogen CEO Michel Vounatsos Joins Quris-AI Board

GlobeNewswire 2023-12-13 Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug L...

GlobeNewswire 2023-11-07 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 2023-10-26 Zai Lab Announces Participation in November Investor Conferences

GlobeNewswire 2023-10-18 Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7,...

GlobeNewswire 2023-09-18 Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injec...

GlobeNewswire 2023-09-04 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...

GlobeNewswire 2023-08-30 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patien...

GlobeNewswire 2023-08-29 Zai Lab Announces Participation in September Investor Conferences

GlobeNewswire 2022-03-23 Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on Marc...

GlobeNewswire 2022-03-22 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited ...

GlobeNewswire 2022-03-21 Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gyne...

GlobeNewswire 2022-03-16 (ZLAB) Alert: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading ZLAB Class Act...

GlobeNewswire 2022-03-15 Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

GlobeNewswire 2022-03-14 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million

GlobeNewswire 2022-03-01 Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

GlobeNewswire 2022-02-17 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

GlobeNewswire 2022-02-15 Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

GlobeNewswire 2022-02-07 Zai Lab Announces Upcoming Presentation at February Investor Conference

GlobeNewswire 2022-01-12 Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor ...

Zai Lab Limited/ US98887Q1040 /

If you wish to receive reply to your feedback, please provide your email address.